Argyle Safety Fistula Cannula With Anti-reflux Valve Clinical Study

Last updated: May 5, 2025
Sponsor: Medtronic - MITG
Overall Status: Completed

Phase

N/A

Condition

N/A

Treatment

Argyle Safety Fistula Cannula with Anti-Reflux Valve

Clinical Study ID

NCT05927532
MDT19046
  • Ages > 18
  • All Genders

Study Summary

The purpose of the investigation is to confirm the safety and performance of the Argyle™ Safety Fistula Cannula with Anti-reflux Valve for hemodialysis treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subject who is aged 18 years or older who signed informed consent

  • Subject is undergoing in-center hemodialysis

  • Subject has an arteriovenous fistulae (AVF) fistula that was determined to be matureby standard clinical definition

Exclusion

Exclusion Criteria:

  • Subject is enrolled in another study that could confound the results of this study,without documented pre-approval

  • Subject with an existing arteriovenous graft

  • Subjects with known allergies to plastics

  • Subjects who are unable to read or respond to the questionnaire about satisfaction

Study Design

Total Participants: 40
Treatment Group(s): 1
Primary Treatment: Argyle Safety Fistula Cannula with Anti-Reflux Valve
Phase:
Study Start date:
March 10, 2024
Estimated Completion Date:
December 15, 2024

Study Description

The study will be performed at up to 5 US hemodialysis clinics.

Qualified patients who choose to participate and sign informed consent will be enrolled in the study. The investigational sites chosen to participate in this study will be trained on the insertion procedure using plastic fistula cannulas according to established curriculum. A combination of didactic training followed by insertion using a cannulation arm will be conducted. Cannulation on consented subjects will begin after the inserter demonstrates proficiency on the cannulation arm. Proficiency definitions are outlined in the protocol. After two supervised (by Medtronic and/or dedicated, trained super user) successful cannulations on consented subjects, the clinician will be permitted to cannulate without supervision.

Data supporting the primary, secondary, and exploratory objectives will be captured following thirty-six (36) hemodialysis sessions for each enrolled subject.

Cannulations will be performed by a minimum of five different clinicians at up to 5 dialysis clinic sites.

The investigational sites chosen to participate in this study will be trained on the insertion procedure using plastic fistula cannulas for a pre-determined period and according to established curriculum. A combination of didactic training followed by insertion using a cannulation arm will be conducted. After two supervised (by Medtronic and/or dedicated, trained super user) successful cannulations on consented subjects, the clinician will be permitted to cannulate without supervision and the data collection for the primary and secondary objectives will begin. Hemodialysis sessions will be performed, according to the investigator's prescription, throughout the duration of the study. Dialysis adequacy will be verified at baseline and during the mid-week session on weeks 1, 3, 6 and 12. Other than the blood sampling, there are no study-specific procedures, other than cannulation with the Argyle™ Safety Fistula Cannula with Anti-Reflux Valve, that will be required.

Connect with a study center

  • DaVita Hartford

    Hartford, Connecticut 06082
    United States

    Site Not Available

  • DaVita Columbus

    Columbus, Georgia 31904
    United States

    Site Not Available

  • DaVita Spartanburg

    Spartanburg, South Carolina 29303
    United States

    Site Not Available

  • DaVita Norfolk

    Norfolk, Virginia 23505
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.